ArticleInternational journal of cardiology. Heart & vasculature2023
Cryoballoon pulmonary vein isolation for atrial fibrillation in obese patients: A non-inferiority analysis.
Article in International journal of cardiology. Heart & vasculature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 13 citations in OpenAlex.
- Phenotype-stratified treatment response in obese atrial fibrillation: Post-hoc cluster analysis of the PRAGUE-25 randomized trial.International journal of cardiology. Heart & vasculature · 2026Article
- Mechanistic insights into the learning curve of cryoballoon ablation: ablation temperature mediates the effect of operator experience on radiation exposure.Frontiers in cardiovascular medicine · 2026Article
- BMI, race and AF recurrence post ablation: a meta-analysis and systematic review.Frontiers in cardiovascular medicine · 2026Review
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
- Recent highlights from the International Journal of Cardiology Heart & Vasculature: cardiometabolic disease.International journal of cardiology. Heart & vasculature · 2025Article
- De novo pulmonary vein isolation in obese vs nonobese patients under deep sedation: Does obesity increase procedure complexity?Heart rhythm O2 · 2025Article
- The Impact of Comorbidities on Pulmonary Function Measured by Spirometry in Patients After Percutaneous Cryoballoon Pulmonary Vein Isolation Due to Atrial Fibrillation.Journal of clinical medicine · 2025Article
- Cryoballoon Pulmonary Vein Isolation in Obese Patients with Atrial Fibrillation Compared to Non-Obese Counterparts: A Meta-Analysis.Biomedicines · 2025Review
- Impact of overweight and obesity on radiation dose and outcome in patients undergoing pulmonary vein isolation by cryoballoon and pulsed field ablation.International journal of cardiology. Heart & vasculature · 2024Article
- Obesity and cardiovascular disease: Risk assessment, physical activity, and management of complications.International journal of cardiology. Cardiovascular risk and prevention · 2024Review
- Impact of Body Mass Index on the Outcomes of Cryoballoon Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation.Clinics and practice · 2024Article
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2024Article
- Obesity as a risk factor in atrial fibrillation and heart failure.Journal of diabetes and metabolic disorders · 2024Review
- Recent highlights on the prevalence and role of sleep disordered breathing in cardiovascular diseases from theInternational journal of cardiology. Heart & vasculature · 2023Article
- Does weight matter in cryoballoon ablation?International journal of cardiology. Heart & vasculature · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with obesity are at higher risk of developing atrial fibrillation (AF) and benefit from radiofrequency ablation. Potentially, cryoballoon ablation (CBA) may be equally effective and safe in such patients. Methods: We conducted a prospective, single-center study to investigate whether CBA for pulmonary vein isolation is as effective and safe in obese patients as it is in non-obese controls. Primary efficacy endpoint was recurrence of AF, atrial flutter or atrial tachycardia after a 90-day blanking period. Safety endpoints were death, stroke or procedure-associated complications. Conduction of a subgroup analysis regarding the impact of additional diabetes was predefined in case the primary efficacy endpoint was met. The study was event driven and powered for noninferiority. Results: A total of 949 patients underwent CBA (251 obese with mean body-mass-index 33.5 ± 3 kg/m Conclusion: CBA is effective and safe in obese and DM patients. Weighing the high cardiovascular risk of obese patients against a reduction of cardiovascular events by early rhythm control, CBA should be offered to this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.